Drug General Information (ID: DDIYL0IGUV)
Drug Name			Mefloquine		Drug Info		Ondansetron		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antimalarial Agents				Antiemetics
Structure

Mechanism of Mefloquine-Ondansetron Interaction (Severity Level: Moderate)
Increased risk of atrioventricular block Click to Show/Hide Mechanism Graph
Drug Name		Mefloquine				Ondansetron
Mechanism		Delay atrioventricular conduction				Delay atrioventricular conduction
Key Mechanism Factor 1
		Factor Name		Atrioventricular block
		Factor Description		Atrioventricular block is a type of cardiac conduction block that occurs when the electrical signal from the atria to the ventricles is impaired. In an Atrioventricular block, this electrical signal is either delayed or completely blocked. When the signal is completely blocked, the ventricles produce their own electrical signal to control the heart rate. The heart rate produced by the ventricles is much slower than that produced by the sinus node.
Mechanism Description		Increased risk of atrioventricular block by the combination of Mefloquine and Ondansetron

Recommended Action
Management		Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes or other arrhythmia such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
3	Canadian Pharmacists Association "e-CPS."